Cover Image

Metabolic effect of blocking sodium-taurocholate co-transporting polypeptide in hypercholesterolemic humans with a twelve-week course of bulevirtide: n exploratory phase I clinical trial

Bile acids (BA) play an important role in cholesterol metabolism and possess further beneficial metabolic effects as signalling molecules. Blocking the hepatocellular uptake of BA via sodium-taurocholate co-transporting polypeptide (NTCP) with the first-in-class drug bulevirtide, we expected to obse...

Full description

Saved in:
Bibliographic Details
Main Authors: Stoll, Felicitas E. (Author) , Seidel-Glätzer, Andrea (Author) , Burghaus, Ina (Author) , Göring, Oliver (Author) , Sauter, Max (Author) , Rose, Peter (Author) , Daniel, Volker (Author) , Haag, Mathias (Author) , Schwab, Matthias (Author) , Riffel, Johannes (Author) , André, Florian (Author) , Taylor, Lenka A. (Author) , Weiß, Johanna (Author) , Burhenne, Jürgen (Author) , Cleeves, Volker (Author) , Haefeli, Walter E. (Author) , Blank, Antje (Author)
Format: Article (Journal)
Language:English
Published: 14 December 2022
In: International journal of molecular sciences
Year: 2022, Volume: 23, Issue: 24, Pages: 1-16
ISSN:1422-0067
DOI:10.3390/ijms232415924
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.3390/ijms232415924
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1422-0067/23/24/15924
Get full text
Author Notes:Felicitas Stoll, Andrea Seidel-Glätzer, Ina Burghaus, Oliver Göring, Max Sauter, Peter Rose, Volker Daniel, Mathias Haag, Matthias Schwab, Johannes Riffel, Florian André, Lenka Taylor, Johanna Weiss, Jürgen Burhenne, Volker Cleeves, Walter E. Haefeli and Antje Blank
Description
Summary:Bile acids (BA) play an important role in cholesterol metabolism and possess further beneficial metabolic effects as signalling molecules. Blocking the hepatocellular uptake of BA via sodium-taurocholate co-transporting polypeptide (NTCP) with the first-in-class drug bulevirtide, we expected to observe a decrease in plasma LDL cholesterol. In this exploratory phase I clinical trial, volunteers with LDL cholesterol > 130 mg/dL but without overt atherosclerotic disease were included. Thirteen participants received bulevirtide 5 mg/d subcutaneously for 12 weeks. The primary aim was to estimate the change in LDL cholesterol after 12 weeks. Secondary endpoints included changes in total cholesterol, HDL cholesterol, lipoprotein(a), inflammatory biomarkers, and glucose after 12 weeks. In addition, cardiac magnetic resonance imaging (CMR) was performed at four time points. BA were measured as biomarkers of the inhibition of hepatocellular uptake.
Item Description:Gesehen am 21.02.2023
Physical Description:Online Resource
ISSN:1422-0067
DOI:10.3390/ijms232415924

Similar Items